

User Driven Development of a New Device for Weekly Growth Hormone Administration in Pediatric Patients

Steen Jensen¹, Henrik Egesborg, PhD¹, Paul Erik Fabricius², Bjarne Sørensen², and Søren Vestergård Jacobsen²

¹Ascendis Pharma A/S, ²Medicom Innovation Partner

This study was sponsored by Ascendis Pharma A/S.



Background

Ascendis Pharma is developing TransCon Growth Hormone, a once-weekly, sustained-release prodrug of recombinant human growth hormone (hGH; somatropin) for the treatment of growth hormone deficiency (GHD) in children and adults.

Current treatment of growth hormone disorders involves daily injections of hGH over many years. Patients are typically diagnosed and initiated on treatment in childhood; adherence is critically important to treatment outcomes. Therefore, hGH administration devices must be simple to use and well accepted. Desirable device characteristics include:


- Simple operation with few user steps
- Weekly, single, low-volume injections (<0.6 mL)
- Small needles (31G, 4mm) comparable to daily hGH devices
- Room temperature storage
- No waste, empty-all design
- Long lifespan
- Bluetooth® connectivity



Methods

Seventy-three subjects, caregivers, health care professionals (HCP) with hGH therapy experience, and other potential users participated in five usability studies conducted in the U.S., Germany, and Denmark.


An initial preference study investigated three model concepts with different cartridge loading steps. Four subsequent studies simulated actual usage of the auto-injector prototypes with increasing functionality.



Half of the subjects and caregivers were trained on how to use the auto-injector by a moderator using the Quick Reference Guide (QRG). The other half of the subjects and caregivers, as well as all HCPs were instead given the QRG and Instructions for Use (IFU) only.

Upon completion of the training or learning, all participants completed one or two full use device sequences, including mounting the needle, inserting the cartridge, initiating automatic reconstitution of the lyophilized formulation, auto-injecting into an injection pad, and removing the empty cartridge.

TransCon hGH Auto-Injector




Results

Subjects indicated a preference for a cartridge loading into the top of the device with the needle attached.

Subjects appreciated key usability features:

- Automatic reconstitution of formulation
- Feedback on reconstitution progress
- No priming or air shot required
- Automatic injection upon needle insertion
- Confirmation of completed injection
- No handling of used needle
- No refrigeration required
- Friendly, comfortable form factor



The TransCon hGH Auto-Injector and cartridge system was well accepted. Consistent device feed-back by sound and LED lit icons was also well understood.

Conclusion

The TransCon hGH Auto-Injector was well accepted, easy to use, and eliminated the need for daily injections, cold storage, priming or air shots, dose settings, and double injections. The electronic device also provided automatic reconstitution and facilitated delivery by auto-injection.

A human factors validation study will be conducted before the auto-injector and cartridge system is included into the ongoing Ascendis Phase 3 heiGHt trial of once weekly TransCon hGH.

